Literature DB >> 3875668

Capsular antigens noncovalently or covalently associated with protein as vaccines to Haemophilus influenzae type b: comparison in two-year-old children.

P Anderson, M Pichichero, R Insel, P Farsad, M Santosham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3875668     DOI： 10.1093/infdis/152.3.634

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  8 in total

1.  Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity.

Authors:  Fan Zhang; Ying-Jie Lu; Richard Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

2.  Impaired IgG2 anti-pneumococcal antibody responses in patients with recurrent infection and normal IgG2 levels but no IgA.

Authors:  P J Lane; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 3.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

4.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

Review 5.  Haemophilus influenzae type b conjugate vaccines.

Authors:  Dominic F Kelly; E Richard Moxon; Andrew J Pollard
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

6.  Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants.

Authors:  R A Insel; P W Anderson
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

Review 7.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

8.  A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.

Authors:  Robert T Cartee; Ann Thanawastien; Thomas J Griffin Iv; John J Mekalanos; Stephan Bart; Kevin P Killeen
Journal:  PLoS Negl Trop Dis       Date:  2020-01-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.